Qilu Pharmaceutical Co., Ltd.

Pharma

Jinan, Shandong, China · Est. 1995

Qilu Pharmaceutical is a Chinese pharmaceutical company focused on the research, development, and commercialization of innovative drugs across multiple therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

178

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

32 drugs in development

Approved4

Phase 322

Phase 29

Phase 15

Preclinical3

By Therapeutic Area

top 6

Oncology

1535%

Hematology

49%

Cardiovascular

49%

Neurology

37%

Metabolic & Endocrine

37%

Nephrology

25%

R&D Momentum

83/100

Pipeline Velocity

66/100

Trial Completion Rate

97/100

Pipeline Concentration

16/100

Pipeline Freshness

72/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Key Events

May 1, 2026TrialQLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Apr 30, 2026TrialQLS5212 for Participants With Advanced Solid Tumors

Apr 20, 2026TrialSafety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Apr 5, 2026TrialA Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

Apr 5, 2026TrialQLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Apr 1, 2026TrialQLS1410 in Participants With Uncontrolled Hypertension

Apr 1, 2026TrialQLS12010 Capsules in Adults With Moderate to Severe Hidradenitis Suppurativa

Apr 1, 2026TrialEfficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes

4 more events

Apr 1, 2026TrialQLS5132 Combination Therapy in Advanced Solid Tumors

Mar 28, 2026TrialStudy of QLS5308 in Patients With Advanced Solid Tumors

Mar 5, 2026TrialQLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis

Mar 5, 2026TrialQLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded1995

HQJinan, Shandong, China

Websiteqilu.com.cn

Therapeutic Focus

oncologycardiovasculargastrointestinal

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(4 drugs)

—

Cardiovascular(4 drugs)

Dermatology(1 drug)

—

Dermatology(1 drug)

Gastroenterology(1 drug)

—

Gastroenterology(1 drug)

Hematology(4 drugs)

—

Hematology(4 drugs)

Immunology(1 drug)

—

Immunology(1 drug)

Metabolic & Endocrine(3 drugs)

—

Metabolic & Endocrine(3 drugs)

Musculoskeletal(2 drugs)

—

Musculoskeletal(2 drugs)

Nephrology(2 drugs)

—

Nephrology(2 drugs)

Neurology(3 drugs)

—

Neurology(3 drugs)

Oncology(15 drugs)

—

Oncology(15 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Psychiatry(1 drug)

—

Psychiatry(1 drug)

Rare Disease(1 drug)

—

Rare Disease(1 drug)

Unknown / Other(4 drugs)

—

Unknown / Other(4 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)